Browse All

Current Filters

CLEAR FILTER x

TITLE

Clinical Characteristics and Outcomes of Neurofascin 186 IgG-associated Neuropathies

The Safety and Efficacy of Chronic Weekly Rozanolixizumab Treatment in Patients with Generalized Myasthenia Gravis (MG0004)

Author:Bril, Vera   Druzdz, Artur   Grosskreutz, Julian   Habib, Ali A.   Kaminski, Henry J.   Mantegazza, Renato   Sacconi, Sabrina   Utsugisawa, Kimiaki   Vu, Tuan   Boehnlein, Marion   Woltering, Franz   Greve, Bernhard   Gayfieva, Maryam   Vissing, John   

Session Name:P4: Autoimmune Neurology: Peripheral Autoimmunity  

Topic:Autoimmune Neurology  

Program Number:P4.017  

Author Institution:University Health Network, Toronto, ON, Canada, Toronto, ON, Canada  Department of Neurology, Municipal Hospital, Poznan, Poland, Swarzedz, Poland  Precision Neurology, Department of Neurology, University of Lübeck, Lübeck, Germany, Lubeck, Germany  MDA ALS and Neuromuscular Center, University of California, Irvine, Irvine, CA, USA, Orange, CA  Department of Neurology & Rehabilitation Medicine, George Washington University, Washington, DC, USA, Washington, DC  Department of Neuroimmunology and Neuromuscular Diseases, Fondazione IRCCS, Istituto Nazionale Neurologico Carlo Besta, Milan, Italy, Milan, Italy  Université Côte d’Azur, Peripheral Nervous System & Muscle Department, Pasteur 2 Hospital, Centre Hospitalier Universitaire de Nice, Nice, France, Nice, France  Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan, Hanamaki, Japan  Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, FL, USA, Tampa, FL  UCB Pharma, Monheim, Germany, Monheim, Germany  UCB Pharma, Monheim, Germany, Monheim Am Rhein, Germany  UCB Pharma, Slough, UK, London, United Kingdom  Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, Copenhagen, Denmark  

Preclinical Pharmacology of S-1117, a Novel Engineered Fc-fused IgG Cleaving Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases

Subacute Inflammatory Demyelinating Polyneuropathy (SIDP) Secondary to Tumor Necrosis Factor (TNF)-Alpha Inhibitor (Adalimumab) for the Treatment of Rheumatoid Arthritis: A Case Report